$LCTX News

Lineage Cell Therapeutics, Inc. (LCTX) Q1 2026 Earnings Call Transcript

Lineage Cell Therapeutics (NYSEARCA:LCTX) Q1 2026 Results: Revenue Miss and Increased Losses Weigh on Investor Sentiment

Lineage Cell Therapeutics Q1 EPS $(0.03) Misses $(0.02) Estimate, Sales $1.725M Miss $3.602M Estimate

Lineage Cell Therapeutics, Inc. (LCTX) Presents at FFB Retinal Therapeutics Innovation Summit - Slideshow

Niagen Bioscience And 2 Additional Promising Penny Stocks For Your Consideration

Lineage Announces Formation of Scientific Advisory Board

Lineage Cell (LCTX) Launches Its Latest Cell Therapy Program

Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease

HC Wainwright & Co. Reiterates Buy on Lineage Cell Therapeutics, Maintains $9 Price Target

Lineage Cell Therapeutics Expands Cell Transplant Pipeline With COR1

Lineage Cell Therapeutics Files Prospectus To Offer Up To $100M In Common Shares, Preferred Shares, Debt, And Warrants

Lineage Cell Therapeutics Files $60M ATM Share Offering Prospectus Supplement

D. Boral Capital Maintains Buy on Lineage Cell Therapeutics, Raises Price Target to $3

Lineage Cell Therapeutics, Inc. Q4 2025 Earnings Call Summary

Lineage Cell Therapeutics Q4 Earnings Call Highlights

Lineage Cell Therapeutics (LCTX) Reports Q4 Revenue Beat and Narrowed Loss

Lineage Cell (LCTX) Reports Break-Even Earnings for Q4

Lineage Cell Therapeutics, Inc. (LCTX) Q4 2025 Earnings Call Transcript

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Lineage Cell Therapeutics Q4 Earnings Summary & Key Takeaways